Stock Price & Volume | Full Chart
30-Day Implied Volatility | IV30 Full Chart
KB Home, Accenture, Netflix And Other Big Stocks Moving Higher On Thursday
Benzinga (Thu, 23-Mar 10:39 AM ET)
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa
Business Wire (Thu, 16-Mar 7:00 AM ET)
Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
Business Wire (Thu, 9-Mar 7:00 AM ET)
FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma
Business Wire (Thu, 2-Mar 7:00 AM ET)
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights
Business Wire (Wed, 1-Mar 7:00 AM ET)
Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease
Business Wire (Tue, 28-Feb 7:00 AM ET)
Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective OKYO Pharma's Drug Candidate Could Be The Solution
News Direct (Thu, 23-Feb 10:42 AM ET)
Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy
Business Wire (Thu, 23-Feb 7:00 AM ET)
Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX-629 Into New Phase 2 Systemic Disease Trials
Business Wire (Thu, 16-Feb 7:00 AM ET)
Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
Business Wire (Thu, 9-Feb 7:00 AM ET)
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Aldeyra Therapeutics trades on the NASDAQ stock market under the symbol ALDX.
As of March 27, 2023, ALDX stock price declined to $8.51 with 679,961 million shares trading.
ALDX has a beta of 1.14, meaning it tends to be more sensitive to market movements. ALDX has a correlation of 0.13 to the broad based SPY ETF.
ALDX has a market cap of $498.35 million. This is considered a Small Cap stock.
In the last 3 years, ALDX stock traded as high as $15.95 and as low as $1.93.
The top ETF exchange traded funds that ALDX belongs to (by Net Assets): VTI, VXF, DWAS, IWC, DFAS.
ALDX has outperformed the market in the last year with a price return of +76.6% while the SPY ETF lost -10.5%. ALDX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +28.9% and +18.5%, respectively, while the SPY returned +4.0% and +3.2%, respectively.
ALDX support price is $8.57 and resistance is $9.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALDX stock will trade within this expected range on the day.